Chemoreirradiation for recurrent salivary gland malignancies
Abstract
Background and purpose
To report our experience in treating recurrent salivary gland malignancies using concurrent chemotherapy and reirradiation.
Materials and methods
Between 1986 and 2007, 14 patients with locoregionally recurrent salivary gland cancer underwent maximal surgical resection followed by adjuvant 5-fluorouracil and hydroxyurea-based chemotherapy concurrently with 1.5
Gy twice daily or 2
Gy daily reirradiation. Each cycle consisted of chemoreirradiation for 5 consecutive days followed by a 9-day break. The median reirradiation dose was 66
Gy (R 30–72
Gy) after a mean radiation treatment interval of 48
months.
Results
The median follow-up for all patients was 18
months (R 2–125
months) and 41
months for survivors. The parotid gland (n
=
6) and minor salivary glands (n
=
6) were involved more commonly than the submandibular gland (n
=
2). Locoregional control at 1 and 3
years was 72.2% and 51.6%, respectively. Actuarial overall survival at 3 and 5
years was 35.7% and 26.8%, respectively. Tracheostomies and feeding tubes were placed in 2 and 8 patients, respectively. Six patients had feeding tubes at last follow-up or death.
Conclusions
Concurrent chemotherapy and reirradiation for recurrent salivary malignancies result in promising locoregional control for patients with recurrent salivary gland malignancies.
Keywords: Salivary malignancy, Reirradiation, Chemoradiotherapy, Head and neck cancer
To access this article, please choose from the options below
PII: S0167-8140(10)00157-X
doi:10.1016/j.radonc.2010.03.006
© 2010 Elsevier Ireland Ltd. All rights reserved.
